Jack Allen
Stock Analyst at Baird
(1.04)
# 3,892
Out of 5,116 analysts
42
Total ratings
41.18%
Success rate
-10.39%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jack Allen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRSP CRISPR Therapeutics AG | Maintains: Neutral | $52 → $44 | $55.08 | -20.12% | 3 | Nov 11, 2025 | |
| VOR Vor Biopharma | Upgrades: Outperform | $20 → $64 | $14.72 | +334.78% | 5 | Oct 15, 2025 | |
| TSHA Taysha Gene Therapies | Maintains: Outperform | $7 → $12 | $5.83 | +105.83% | 5 | Oct 2, 2025 | |
| FATE Fate Therapeutics | Maintains: Neutral | $5 → $4 | $1.00 | +300.00% | 2 | May 14, 2025 | |
| ALLO Allogene Therapeutics | Maintains: Outperform | $12 → $9 | $1.38 | +552.17% | 3 | May 14, 2025 | |
| INKT MiNK Therapeutics | Maintains: Outperform | $80 → $40 | $11.95 | +234.73% | 2 | Nov 15, 2024 | |
| ACLX Arcellx | Maintains: Outperform | $77 → $106 | $65.71 | +61.31% | 5 | Nov 6, 2024 | |
| NTLA Intellia Therapeutics | Maintains: Neutral | $24 → $18 | $9.44 | +90.68% | 2 | Oct 25, 2024 | |
| TIL Instil Bio | Reiterates: Outperform | $180 | $11.31 | +1,491.51% | 9 | Sep 16, 2024 | |
| MREO Mereo BioPharma Group | Initiates: Outperform | $8 | $2.31 | +246.32% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $84 | $36.13 | +132.49% | 1 | Oct 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $5 | $1.65 | +203.03% | 1 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $4.75 | - | 2 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $6 → $9 | $4.08 | +120.59% | 1 | Oct 7, 2021 |
CRISPR Therapeutics AG
Nov 11, 2025
Maintains: Neutral
Price Target: $52 → $44
Current: $55.08
Upside: -20.12%
Vor Biopharma
Oct 15, 2025
Upgrades: Outperform
Price Target: $20 → $64
Current: $14.72
Upside: +334.78%
Taysha Gene Therapies
Oct 2, 2025
Maintains: Outperform
Price Target: $7 → $12
Current: $5.83
Upside: +105.83%
Fate Therapeutics
May 14, 2025
Maintains: Neutral
Price Target: $5 → $4
Current: $1.00
Upside: +300.00%
Allogene Therapeutics
May 14, 2025
Maintains: Outperform
Price Target: $12 → $9
Current: $1.38
Upside: +552.17%
MiNK Therapeutics
Nov 15, 2024
Maintains: Outperform
Price Target: $80 → $40
Current: $11.95
Upside: +234.73%
Arcellx
Nov 6, 2024
Maintains: Outperform
Price Target: $77 → $106
Current: $65.71
Upside: +61.31%
Intellia Therapeutics
Oct 25, 2024
Maintains: Neutral
Price Target: $24 → $18
Current: $9.44
Upside: +90.68%
Instil Bio
Sep 16, 2024
Reiterates: Outperform
Price Target: $180
Current: $11.31
Upside: +1,491.51%
Mereo BioPharma Group
Jun 13, 2024
Initiates: Outperform
Price Target: $8
Current: $2.31
Upside: +246.32%
Oct 31, 2023
Initiates: Outperform
Price Target: $84
Current: $36.13
Upside: +132.49%
Nov 2, 2022
Initiates: Outperform
Price Target: $5
Current: $1.65
Upside: +203.03%
May 18, 2022
Upgrades: Outperform
Price Target: n/a
Current: $4.75
Upside: -
Oct 7, 2021
Upgrades: Outperform
Price Target: $6 → $9
Current: $4.08
Upside: +120.59%